Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 5.42%
As of Tuesday, October 20, Structure Therapeutics Inc.’s GPCR share price has surged by 5.42%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,300.8 | $436.9 | 49% |
|
| Shares Out (Mil) | 72.9 | 46.5 | 55% |
|
| Institutional Ownership | 97.1% | 82.2% | 72% |
|
| Float (Mil) | 55.5 | 47.7 | 49% |
|
| Beta | -1.20 | 0.68 | 1% |
|
| Avg Daily Volume (000s) | 1,078 | 339 | 69% |
|
| Price Change (52-week) |
(50.7%) | 52.1% | 20% |
|
| Growth | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.6% | na |
|
| Net Income (5yr) | (54.8%) | (1.6%) | 6% |
|
| EPS (5yr) | 20.9% | 15.1% | 70 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 34.0% | (15.1%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 9 | |
| Current EPS | ($0.686) | ($2.186) | ($2.503) | |
| Month Ago EPS | ($0.504) | ($1.610) | ($2.113) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.493) | ($1.548) | ($2.115) | |
| Year/Year Chg | (65.5%) | (8.3%) | (12.9%) | |
| Financials | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $289 | na |
|
| Net Income (TTM) (Mil) | ($294) | ($11) | 4% |
|
| EPS (TTM) | ($4.178) | ($0.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($271) | ($7) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $119 | $1 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 23% |
|
| Enterprise Value (Q1) (Mil) | $96 | $331 | 22% |
|
| Valuation | GPCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.06 | 2.15 | 29% |
|
| P/E | na | 24.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | GPCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (27.1%) | (23.3%) | 17% |
|
| ROE | (29.5%) | (24.7%) | 20% |
|
| Liabilities to Assets | 8.4% | 31.8% | 5% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 11/17/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.6 |
| Performance Since Inception: | 2.1% |
| +/- S&P 500: | -5.3 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors